Direct-Acting Antivirals-Based Therapy Decreases Hepatic Fibrosis Serum Biomarker Microfibrillar-Associated Protein 4 in Hepatitis C Patients

Clinical and molecular hepatology - South Korea
doi 10.3350/cmh.2018.0029
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Korean Association for the Study of the Liver

Related search

Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Virus Therapy With Direct-Acting Antivirals

Journal of Hepatology
Hepatology
2017English

Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

Oncologist
Cancer ResearchMedicineOncology
2018English

Hepatitis B Reactivation in Chronic Hepatitis C Patients Treated With Interferon or Pan-Oral Direct-Acting Antivirals

Hepatology
MedicineHepatology
2017English

Treating Hepatitis B Virus/Hepatitis C Virus Coinfected Patients With Direct-Acting Hepatitis C Virus Antivirals Only Is Not Safe

Hepatology
MedicineHepatology
2016English

Concomitant Use of Direct-Acting Antivirals and Chemotherapy in Hepatitis C Virus-Infected Patients With Cancer

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2016English

Hepatitis C Related Hepatocellular Carcinoma in the Era of Direct-Acting Antivirals

Hepatoma Research
2018English

Hepatitis C Infected Patients Need Vitamin D3 Supplementation in the Era of Direct Acting Antivirals Treatment

World Journal of Gastroenterology
MedicineGastroenterology
2017English

The Interplay Between Direct-Acting Antivirals and Hepatocellular Carcinoma in Chronic Hepatitis C

Hepatoma Research
2020English

Editorial: Direct-Acting Antivirals Decrease the Frequency of Diabetes Complications in Patients With Chronic Hepatitis C

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy